Preliminary study on the effect of nucleolin specific aptamer-miRNA let-7d chimera on Janus kinase-2 expression level and activity in gastric cancer (MKN-45) cells.
Humans
Aptamers, Nucleotide
/ genetics
Cell Line, Tumor
Gene Expression Regulation
/ genetics
Gene Expression Regulation, Neoplastic
/ genetics
Janus Kinase 2
/ genetics
MicroRNAs
/ genetics
Phosphoproteins
/ genetics
Preliminary Data
Proto-Oncogene Mas
RNA-Binding Proteins
/ genetics
Stomach Neoplasms
/ genetics
Nucleolin
Gastric cancer
Janus kinase-2 (JAK-2)
MiRNA let-7d
Nucleolin specific aptamer (NCL-Apt)
Journal
Molecular biology reports
ISSN: 1573-4978
Titre abrégé: Mol Biol Rep
Pays: Netherlands
ID NLM: 0403234
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
15
08
2018
accepted:
01
11
2018
pubmed:
12
11
2018
medline:
2
7
2019
entrez:
12
11
2018
Statut:
ppublish
Résumé
Recently, much attention has been focused on the use of miRNAs in cancer treatment. The role of proto-oncogene Janus kinase-2 (JAK-2) in proliferation and survival of gastric cancer has been previously documented. The aim of this study was to evaluate the effect of a chimera consisted of nucleolin specific aptamer (NCL-Apt) and miRNA let-7d on JAK2 expression level and activity in gastric cancer cells. NCL-Apt-miRNA let-7d chimera was prepared by two methods. Gastric cancer (MKN-45) cell line and control cell line of human dermal fibroblast (HDF) were treated with the chimera and the changes in JAK2 expression and activity were determined using real-time PCR and ELISA techniques, respectively. In MKN-45 cells, the chimera caused significant decrease in JAK2 expression level and activity compared to the aptamer alone and miRNA mimic negative control. Nevertheless, transfected miRNA let-7d showed remarkable reduction in the expression level of JAK2 in comparison with control state in both MKN-45 and HDF, confirmed unspecific effect of let-7d on normal and cancerous cells. With regard to the synergic effect of this chimera on JAK2 activity, it might be viewed as a therapeutic candidate in gastric cancer. However, further studies are warranted to prove it.
Identifiants
pubmed: 30415442
doi: 10.1007/s11033-018-4462-7
pii: 10.1007/s11033-018-4462-7
doi:
Substances chimiques
Aptamers, Nucleotide
0
JAK2 protein, human
EC 2.7.10.2
Janus Kinase 2
EC 2.7.10.2
MAS1 protein, human
0
MicroRNAs
0
mirnlet7 microRNA, human
0
Phosphoproteins
0
Proto-Oncogene Mas
0
RNA-Binding Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
207-215Subventions
Organisme : Shahid Beheshti University of Medical Sciences
ID : 12890
Références
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65(2):87–108
doi: 10.3322/caac.21262
pubmed: 25651787
Khademloo M, Moosazadeh M, Ahmadi M, Alizadeh-Navaei R (2018) Geographical distribution of gastric cancer in north of Iran—a cross-sectional study. World Cancer Res J 5(1):e1050
Dong H, Lei J, Ding L, Wen Y, Ju H, Zhang X (2013) MicroRNA: function, detection, and bioanalysis. Chem Rev 113(8):6207–6233
doi: 10.1021/cr300362f
pubmed: 23697835
Ambros V (2004) The functions of animal microRNAs. Nature 431(7006):350–355
doi: 10.1038/nature02871
pubmed: 15372042
Filipowicz W, Bhattacharyya SN, Sonenberg N (2008) Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight. Nat Rev Genet 9(2):102–114
doi: 10.1038/nrg2290
pubmed: 18197166
Zhang B, Pan X, Cobb GP, Anderson TA (2007) MicroRNAs as oncogenes and tumor suppressors. Dev Biol 302(1):1–12
doi: 10.1016/j.ydbio.2006.08.028
pubmed: 16989803
Kwak PB, Iwasaki S, Tomari Y (2010) The microRNA pathway and cancer. Cancer Sci 101(11):2309–2315
doi: 10.1111/j.1349-7006.2010.01683.x
pubmed: 20726859
Link A, Schirrmeister W, Langner C, Varbanova M, Bornschein J, Wex T, Malfertheiner P (2015) Differential expression of microRNAs in preneoplastic gastric mucosa. Sci Rep 5:8270
doi: 10.1038/srep08270
pubmed: 25652892
pmcid: 4317705
Oom AL, Humphries BA, Yang C (2014) MicroRNAs: novel players in cancer diagnosis and therapies. BioMed Res Int. https://doi.org/10.1155/2014/959461
doi: 10.1155/2014/959461
pubmed: 25101302
pmcid: 4101974
Schulman BRM, Esquela-Kerscher A, Slack FJ (2005) Reciprocal expression of lin-41 and the microRNAs let-7 and mir-125 during mouse embryogenesis. Dev Dyn 234(4):1046–1054
doi: 10.1002/dvdy.20599
pubmed: 16247770
pmcid: 2596717
Sokol NS, Xu P, Jan Y-N, Ambros V (2008) Drosophila let-7 microRNA is required for remodeling of the neuromusculature during metamorphosis. Genes Dev 22(12):1591–1596
doi: 10.1101/gad.1671708
pubmed: 18559475
pmcid: 2428057
Johnson CD, Esquela-Kerscher A, Stefani G, Byrom M, Kelnar K, Ovcharenko D, Wilson M, Wang X, Shelton J, Shingara J (2007) The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res 67(16):7713–7722
doi: 10.1158/0008-5472.CAN-07-1083
pubmed: 17699775
Zhang H-H, Wang X-J, Li G-X, Yang E, Yang N-M (2007) Detection of let-7a microRNA by real-time PCR in gastric carcinoma. World J Gastroenterol 13(20):2883
doi: 10.3748/wjg.v13.i20.2883
pubmed: 17569129
pmcid: 4395645
Akao Y, Nakagawa Y, Naoe T (2006) Let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. Biol Pharm Bull 29(5):903–906
doi: 10.1248/bpb.29.903
pubmed: 16651716
Garzon R, Garofalo M, Martelli MP, Briesewitz R, Wang L, Fernandez-Cymering C, Volinia S, Liu C-G, Schnittger S, Haferlach T (2008) Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci USA 105(10):3945–3950
doi: 10.1073/pnas.0800135105
pubmed: 18308931
Park S-M, Shell S, Radjabi AR, Schickel R, Feig C, Boyerinas B, Dinulescu DM, Lengyel E, Peter ME (2007) Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2. Cell Cycle 6(21):2585–2590
doi: 10.4161/cc.6.21.4845
pubmed: 17957144
Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D, Slack FJ (2005) RAS is regulated by the let-7 microRNA family. Cell 120(5):635–647
doi: 10.1016/j.cell.2005.01.014
pubmed: 15766527
Sampson VB, Rong NH, Han J, Yang Q, Aris V, Soteropoulos P, Petrelli NJ, Dunn SP, Krueger LJ (2007) MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Res 67(20):9762–9770
doi: 10.1158/0008-5472.CAN-07-2462
pubmed: 17942906
Wang Y, Lu Y, Toh ST, Sung W-K, Tan P, Chow P, Chung AY, Jooi LL, Lee CG (2010) Lethal-7 is down-regulated by the hepatitis B virus x protein and targets signal transducer and activator of transcription 3. J Hepatol 53(1):57–66
doi: 10.1016/j.jhep.2009.12.043
pubmed: 20447714
Wang Z, Lin S, Li JJ, Xu Z, Yao H, Zhu X, Xie D, Shen Z, Sze J, Li K (2011) MYC protein inhibits transcription of the microRNA cluster MC-let-7a-1∼ let-7d via noncanonical E-box. J Biol Chem 286(46):39703–39714
doi: 10.1074/jbc.M111.293126
pubmed: 21903590
pmcid: 3220549
Childs G, Fazzari M, Kung G, Kawachi N, Brandwein-Gensler M, McLemore M, Chen Q, Burk RD, Smith RV, Prystowsky MB (2009) Low-level expression of microRNAs let-7d and miR-205 are prognostic markers of head and neck squamous cell carcinoma. Am J Pathol 174(3):736–745
doi: 10.2353/ajpath.2009.080731
pubmed: 19179615
pmcid: 2665736
Mu G, Liu H, Zhou F, Xu X, Jiang H, Wang Y, Qu Y (2010) Correlation of overexpression of HMGA1 and HMGA2 with poor tumor differentiation, invasion, and proliferation associated with let-7 down-regulation in retinoblastomas. Hum Pathol 41(4):493–502
doi: 10.1016/j.humpath.2009.08.022
pubmed: 20004941
Volinia S, Galasso M, Sana ME, Wise TF, Palatini J, Huebner K, Croce CM (2012) Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA. Proc Natl Acad Sci USA 109(8):3024–3029
doi: 10.1073/pnas.1200010109
pubmed: 22315424
Di Fiore R, Drago-Ferrante R, Pentimalli F, Di Marzo D, Forte IM, Carlisi D, De Blasio A, Tesoriere G, Giordano A, Vento R (2016) Let-7d miRNA shows both antioncogenic and oncogenic functions in osteosarcoma-derived 3AB-OS cancer stem cells. J Cell Physiol 231(8):1832–1841
doi: 10.1002/jcp.25291
pubmed: 26679758
Hertel J, Bartschat S, Wintsche A, Otto C, of the Bioinformatics Computer Lab TS, Stadler PF (2012) Evolution of the let-7 microRNA family. RNA Biol 9(3):231–241
doi: 10.4161/rna.18974
pubmed: 22617875
pmcid: 3384580
Verma A, Kambhampati S, Parmar S, Platanias LC (2003) Jak family of kinases in cancer. Cancer Metastasis Rev 22(4):423–434
doi: 10.1023/A:1023805715476
pubmed: 12884916
Ding L, Xu Y, Zhang W, Deng Y, Si M, Du Y, Yao H, Liu X, Ke Y, Si J (2010) MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2. Cell Res 20(7):784
doi: 10.1038/cr.2010.79
pubmed: 20548334
Judd LM, Menheniott TR, Ling H, Jackson CB, Howlett M, Kalantzis A, Priebe W, Giraud AS (2014) Inhibition of the JAK2/STAT3 pathway reduces gastric cancer growth in vitro and in vivo. PLoS ONE 9(5):e95993
doi: 10.1371/journal.pone.0095993
pubmed: 24804649
pmcid: 4013079
Miao L, Liu K, Xie M, Xing Y, Xi T (2014) miR-375 inhibits Helicobacter pylori-induced gastric carcinogenesis by blocking JAK2–STAT3 signaling. Cancer Immunol Immunother 63(7):699–711
doi: 10.1007/s00262-014-1550-y
pubmed: 24718681
Ramezanpour M, Daei P, Khanaki K, Hosseinabadi T, Tabarzad M (2017) The relationship between Janus kinase pathways and microRNAs. Trends Pept Protein Sci 1(4):144–152
Wu H, Huang M, Cao P, Wang T, Shu Y, Liu P (2012) MiR-135a targets JAK2 and inhibits gastric cancer cell proliferation. Cancer Biol Ther 13(5):281–288
doi: 10.4161/cbt.18943
pubmed: 22310976
Kanwar JR, Roy K, Kanwar RK (2011) Chimeric aptamers in cancer cell-targeted drug delivery. Crit Rev Biochem Mol Biol 46(6):459–477
doi: 10.3109/10409238.2011.614592
pubmed: 21955150
pmcid: 3233271
Bates PJ, Laber DA, Miller DM, Thomas SD, Trent JO (2009) Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp Mol Pathol 86(3):151–164
doi: 10.1016/j.yexmp.2009.01.004
pubmed: 19454272
pmcid: 2716701
Reyes-Reyes EM, Teng Y, Bates PJ (2010) A new paradigm for aptamer therapeutic AS1411 action: uptake by macropinocytosis and its stimulation by a nucleolin-dependent mechanism. Cancer Res. 70:8617–8629
doi: 10.1158/0008-5472.CAN-10-0920
Hovanessian AG, Soundaramourty C, El Khoury D, Nondier I, Svab J, Krust B (2010) Surface expressed nucleolin is constantly induced in tumor cells to mediate calcium-dependent ligand internalization. PLoS ONE 5(12):e15787
doi: 10.1371/journal.pone.0015787
pubmed: 21203423
pmcid: 3009748
Watanabe T, Hirano K, Takahashi A, Yamaguchi K, Beppu M, Fujiki H, Suganuma M (2010) Nucleolin on the cell surface as a new molecular target for gastric cancer treatment. Biol Pharm Bull 33(5):796–803
doi: 10.1248/bpb.33.796
pubmed: 20460757
Soundararajan S, Chen W, Spicer EK, Courtenay-Luck N, Fernandes DJ (2008) The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells. Cancer Res 68(7):2358–2365
doi: 10.1158/0008-5472.CAN-07-5723
pubmed: 18381443
Girvan AC, Teng Y, Casson LK, Thomas SD, Jüliger S, Ball MW, Klein JB, Pierce WM, Barve SS, Bates PJ (2006) AGRO100 inhibits activation of nuclear factor-κB (NF-κB) by forming a complex with NF-κB essential modulator (NEMO) and nucleolin. Mol Cancer Ther 5(7):1790–1799
doi: 10.1158/1535-7163.MCT-05-0361
pubmed: 16891465
Viswanathan SR, Daley GQ, Gregory RI (2008) Selective blockade of microRNA processing by Lin28. Science 320(5872):97–100
doi: 10.1126/science.1154040
pubmed: 18292307
pmcid: 3368499
Herranz H, Cohen SM (2010) MicroRNAs and gene regulatory networks: managing the impact of noise in biological systems. Genes Dev 24(13):1339–1344
doi: 10.1101/gad.1937010
pubmed: 20595229
pmcid: 2895193
Daei P, Ramezanpour M, Khanaki K, Tabarzad M, Nikokar I, Hedayati M, Elmi A (2018) Aptamer-based targeted delivery of miRNA let-7d to gastric cancer cells as a novel anti-tumor therapeutic agent. Iran J Pharm Sci 17(4):1537–1549
Li WX (2008) Canonical and non-canonical JAK–STAT signaling. Trends Cell Biol 18(11):545–551
doi: 10.1016/j.tcb.2008.08.008
pubmed: 18848449
pmcid: 3082280
Zhang Y, Meng X, Shi H, Li W, Ming Z, Zhong Y, Deng W, Zhang Q, Fan N, Niu Z (2016) The role of JAK/STAT3 signaling pathway on apoptosis of lung adenocarcinoma cell line PC-9 induced by icotinib. Am J Transl Res 8(4):1730
pubmed: 27186296
pmcid: 4859901
Khanna P, Chua PJ, Bay BH, Baeg GH (2015) The JAK/STAT signaling cascade in gastric carcinoma. Int J Oncol 47(5):1617–1626
doi: 10.3892/ijo.2015.3160
pubmed: 26398764
Valentino L, Pierre J (2006) JAK/STAT signal transduction: regulators and implication in hematological malignancies. Biochem Pharmacol 71(6):713–721
doi: 10.1016/j.bcp.2005.12.017
pubmed: 16426581
Yu L, Zhu Y, Qiao M, Zhong J, Tu S, Wu Y (2004) Constitutive activation and clinical significance of Stat3 in human gastric cancer tissues and cell lines. Zhonghua yi xue za zhi 84(24):2064–2069
pubmed: 15730617
Vera J, Rateitschak K, Lange F, Kossow C, Wolkenhauer O, Jaster R (2011) Systems biology of JAK-STAT signalling in human malignancies. Prog Biophys Mol Biol 106(2):426–434
doi: 10.1016/j.pbiomolbio.2011.06.013
pubmed: 21762720
Hedvat M, Huszar D, Herrmann A, Gozgit JM, Schroeder A, Sheehy A, Buettner R, Proia D, Kowolik CM, Xin H (2009) The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 16(6):487–497
doi: 10.1016/j.ccr.2009.10.015
pubmed: 19962667
pmcid: 2812011
Barh D, Malhotra R, Ravi B, Sindhurani P (2010) MicroRNA let-7: an emerging next-generation cancer therapeutic. Curr Oncol 17(1):70
doi: 10.3747/co.v17i1.356
pubmed: 20179807
pmcid: 2826782
Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, Harano T, Yatabe Y, Nagino M, Nimura Y (2004) Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 64(11):3753–3756
doi: 10.1158/0008-5472.CAN-04-0637
pubmed: 15172979
Liang S, He L, Zhao X, Miao Y, Gu Y, Guo C, Xue Z, Dou W, Hu F, Wu K (2011) MicroRNA let-7f inhibits tumor invasion and metastasis by targeting MYH9 in human gastric cancer. PLoS ONE 6(4):e18409
doi: 10.1371/journal.pone.0018409
pubmed: 21533124
pmcid: 3078939
Su B, Zhao W, Shi B, Zhang Z, Yu X, Xie F, Guo Z, Zhang X, Liu J, Shen Q (2014) Let-7d suppresses growth, metastasis, and tumor macrophage infiltration in renal cell carcinoma by targeting COL3A1 and CCL7. Mol Cancer 13(1):206
doi: 10.1186/1476-4598-13-206
pubmed: 25193015
pmcid: 4168121
Meng F, Henson R, Wehbe-Janek H, Smith H, Ueno Y, Patel T (2007) The MicroRNA let-7a modulates interleukin-6-dependent STAT-3 survival signaling in malignant human cholangiocytes. J Biol Chem 282(11):8256–8264
doi: 10.1074/jbc.M607712200
pubmed: 17220301
Wei R, Yang Q, Han B, Li Y, Yao K, Yang X, Chen Z, Yang S, Zhou J, Li M (2017) microRNA-375 inhibits colorectal cancer cells proliferation by downregulating JAK2/STAT3 and MAP3K8/ERK signaling pathways. Oncotarget 8(10):16633
doi: 10.18632/oncotarget.15114
pubmed: 28186962
pmcid: 5369990
Wang X, Qiu W, Zhang G, Xu S, Gao Q, Yang Z (2015) MicroRNA-204 targets JAK2 in breast cancer and induces cell apoptosis through the STAT3/BCl-2/survivin pathway. Int J Clin Exp Pathol 8(5):5017
pubmed: 26191195
pmcid: 4503067
Navarro A, Diaz T, Martinez A, Gaya A, Pons A, Gel B, Codony C, Ferrer G, Martinez C, Montserrat E (2009) Regulation of JAK2 by miR-135a: prognostic impact in classic Hodgkin lymphoma. Blood 114(14):2945–2951
doi: 10.1182/blood-2009-02-204842
pubmed: 19666866
Esposito CL, Nuzzo S, Catuogno S, Romano S, de Nigris F, de Franciscis V (2017) STAT3 gene silencing by Aptamer-siRNA chimera as selective therapeutic for glioblastoma. Mol Ther-Nucleic Acids 10 398–411
Esposito CL, Cerchia L, Catuogno S, De Vita G, Dassie JP, Santamaria G, Swiderski P, Condorelli G, Giangrande PH, De Franciscis V (2014) Multifunctional aptamer-miRNA conjugates for targeted cancer therapy. Mol Ther 22(6):1151–1163
doi: 10.1038/mt.2014.5
pubmed: 24441398
pmcid: 4048903